clinical trial results

Aclaris Therapeutics will present previously unreported Phase 2a trial results for ATI-2138, an oral dual ITK/JAK3 inhibitor, at the 2026 AAD Annual Meeting in Denver.

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.

Four companies face April 6, 2026 lead plaintiff deadline in shareholder lawsuits alleging disclosure violations involving valuations, clinical trials, and fraudulent promotion.

PMV Pharmaceuticals reports 50% response rate for ovarian cancer drug rezatapopt, but faces funding pressure with cash runway extending only to Q2 2027.

Roche's obesity drug petrelintide achieved 10.7% weight loss in Phase 2 trials but significantly trails GLP-1 rivals Novo Nordisk and Eli Lilly, triggering sharp stock declines.

DBV Technologies announced strong Phase 3 data for VIASKIN® Peanut patch, with 82.8% of treated children showing improved tolerance. FDA submission planned for H1 2026.

Bristol Myers Squibb's experimental breast cancer drug showed survival improvements in advanced patients, though stock declined slightly following the announcement.

argenx's VYVGART met its primary endpoint in a Phase 3 ocular myasthenia gravis trial, showing significant symptom improvements. The company plans FDA approval for label expansion.

Fulcrum's pociredir shows strong fetal hemoglobin gains in sickle cell Phase 1b trial, with 58% of patients reaching therapeutic levels and reduced pain crises.

OKYO Pharma's urcosimod earns ARVO 2026 presentation slot for neuropathic eye pain therapy. Phase 2a data shows pain reduction and quality-of-life improvements; Phase 2b/3 trial planned for 2026.

Pfizer's 6.3% dividend yield depends on GLP-1 drug success and managing upcoming patent cliffs as it competes against rivals Novo Nordisk and Eli Lilly in obesity treatments.